Last updated: July 9, 2023
Sponsor: University of Malaya
Overall Status: Active - Recruiting
Phase
2/3
Condition
Kidney Failure
Kidney Disease
Renal Failure
Treatment
Frusemide
Aminophylline
Clinical Study ID
NCT05933642
202334-12198
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients aged 18 years old and above who are admitted to the ICU of UMMC during thestudy period
- Oliguric patients, with the need for improved diuresis at clinician discretion -defined as urine output <0.5ml/kg/hour
Exclusion
Exclusion Criteria:
- Patient refusal for participation of study
- Patients with known hypersensitivity reaction to aminophylline or furosemide
- Patients with history of tachyarrhythmias, seizures, aspartate aminotransferase oralanine aminotransferase > 3 times normal, or hypothyroidism. Patient with existing peptic ulcer disease or coagulopathy with INR > 1.5
Study Design
Total Participants: 132
Treatment Group(s): 2
Primary Treatment: Frusemide
Phase: 2/3
Study Start date:
July 02, 2023
Estimated Completion Date:
December 31, 2023
Connect with a study center
University of Malaya
Kuala Lumpur, 50603
MalaysiaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.